Innovotech Inc. Commences Trading on OTCQB, Enhancing U.S. Investor Access
Innovotech Inc. has begun trading on the OTCQB Market under symbol IOTCF, expanding its reach to U.S. investors following strong 2025 performance driven by organic growth and strategic acquisitions.
Innovotech Inc., a diversified life sciences technology company, announced that its common shares have commenced trading on the OTCQB Market in the United States under the symbol IOTCF. The company's shares will continue to trade on the TSX Venture Exchange under the symbol IOT. This move represents a strategic step to broaden the company's investor base and increase visibility in U.S. capital markets.
"Listing on the OTCQB allows us to more effectively engage with U.S. investors as we build a larger, more diversified life sciences platform," said Craig Milne, Chief Executive Officer of Innovotech Inc. The company recently reported strong operational progress and financial performance in 2025, including a significant increase in revenues driven by both organic growth and the full-year contribution from the acquisition of Keystone Labs Inc., executed in November 2024. Innovotech delivered consistent revenues across all quarters, reflecting improved scale, operational execution, and a more diversified revenue base.
During 2025, Innovotech successfully integrated Keystone into its operations, materially expanding its analytical chemistry and testing capabilities and strengthening its Canadian customer base. Subsequent to year-end, the company completed the amalgamation of its operating entities, simplifying its corporate structure and positioning the business as a single, integrated laboratory platform. Innovotech also strengthened its balance sheet through the exercise of warrants and the issuance of a convertible debenture, providing additional capital to support equipment purchases, operational expansion, and strategic initiatives.
The company invested meaningfully in laboratory infrastructure, removing capacity bottlenecks and expanding technical capabilities through the acquisition of advanced analytical and microbiology equipment. Innovotech's differentiation is rooted in its depth of expertise in antimicrobial testing and biofilm-related research, supported by accredited quality systems and the ability to execute complex, custom testing programs. The company is frequently engaged on technically challenging projects requiring reproducibility, regulatory awareness, and close collaboration with client development teams, resulting in long-standing customer relationships and higher-value contract research work.
In addition to services, Innovotech manufactures and sells laboratory consumables, including its MBEC Assay® platform, which is used globally in biofilm and antimicrobial research. The company also maintains an active research and development program focused on expanding assay offerings and advancing proprietary technologies, including its InnovoSIL™ antimicrobial silver platform. As it enters 2026, Innovotech is focused on continued organic growth, expansion of service offerings, and disciplined execution of its strategic priorities. The company is actively evaluating a pipeline of acquisition opportunities and continues to invest in infrastructure, people, and systems to support scale.
Innovotech is expanding investor outreach efforts in the United States following its OTCQB listing. "We are building Innovotech deliberately," added Dr. Milne. "Our focus is on long-term value creation through operational excellence, differentiated capabilities, and disciplined growth. We look forward to introducing Innovotech to a broader U.S. investor audience and sharing our progress as we continue to execute." The company operates through ISO-certified and GMP-accredited laboratories, supporting clients across multiple sectors and geographies, delivering reliable, decision-enabling data aligned with regulatory expectations such as those of the U.S. Food and Drug Administration and Health Canada. Learn more about the company at https://www.innovotech.ca.